Transpl Int . In Vitro and In Vivo Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients

[tetano]

Transpl Int


. 2024 Jul 16:37:13272.
doi: 10.3389/ti.2024.13272. eCollection 2024. In Vitro and In Vivo Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients

Ilies Benotmane[SUP] #[/SUP][SUP] 1 2 [/SUP], Martin Jungbauer-Groznica[SUP] #[/SUP][SUP] 3 4 5 [/SUP], Isabelle Staropoli[SUP] 3 [/SUP], Delphine Planas[SUP] 3 [/SUP], Océane Dehan[SUP] 6 7 [/SUP], Angela Brisebarre[SUP] 6 7 [/SUP], Etienne Simon-Loriere[SUP] 6 7 [/SUP], Samira Fafi-Kremer[SUP] 2 8 [/SUP], Olivier Schwartz[SUP] 3 9 [/SUP], Timothée Bruel[SUP] 3 4 9 [/SUP], Sophie Caillard[SUP] 1 2 [/SUP]



Affiliations

• PMID: 39081903
• PMCID: PMC11286486
• DOI: 10.3389/ti.2024.13272

No abstract available Keywords: COVID-19; SARS-CoV-2; immunocompromised; kidney transplant recipients; monoclonal antibodies; sotrovimab.

​